MSCL — Satellos Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- CA$95.20m
- CA$39.25m
- 45
- 26
- 51
- 35
Annual cashflow statement for Satellos Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Net Income/Starting Line | -1.11 | -12.4 | -8.7 | -11.8 | -20.5 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.071 | 8.72 | 3.39 | 0.75 | 3.01 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.361 | -0.499 | 0.662 | 0.273 | -0.748 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.676 | -4.02 | -4.39 | -10.7 | -18.2 |
| Capital Expenditures | 0 | -0.006 | -0.003 | -13 | -27.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 1.39 | 0 | — | 31.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0 | 1.39 | -0.003 | -13 | 4.63 |
| Financing Cash Flow Items | — | 5.33 | 0 | 0.378 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 5.94 | 2.13 | 37.8 | 39 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.69 | 3.31 | -2.26 | 14.9 | 26 |